Listen: Live! From JPM 2024
This week on "The Readout LOUD" podcast, live from #JPM24: A spate of deals and some intermittent sunshine seem to have brightened the 2024 outlook for biotech.
Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recording from the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit.
What's Your Reaction?
